DFTX — Definium Therapeutics, Inc.

—
Nasdaq · Materials · Chemicals · CIK 1813814 ·
Last close
$29.38
Market Cap
$4.02B
52W High
$49.70
52W Low
$10.47
ADV30
1,736,432
Next earnings
2026-11-09
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -72,279,000 -50,961,000 1,074,283,000 241,150,000 106,249,000
Jun 2026 0 — -75,077,000 -158,986,000 1,112,899,000 655,267,000 194,220,000
Mar 2026 0 — -59,220,000 -77,098,000 401,293,000 262,518,000 122,444,000
Dec 2025 0 — -47,578,000 -50,436,000 440,100,000 257,837,000 107,773,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-191,364,000
Investing CF
$-612,550,000
Financing CF
$1,025,107,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.39
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-869,717,000
Inventory
—
Receivables
—
ST Investments
$805,698,000
EBIT TTM
$-332,585,000
Pretax Income TTM
$-337,481,000
Interest Exp TTM
$4,896,000
Analysts
18

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -166,309,000 -183,793,000 440,100,000 107,773,000 332,327,000 -131,560,000
Dec 2024 0 -103,916,000 -108,679,000 302,151,000 60,703,000 241,448,000 -79,129,000
Dec 2023 0 -93,866,000 -95,732,000 124,541,000 46,407,000 78,134,000 -64,365,000
Dec 2022 0 -66,331,000 -56,796,000 169,993,000 19,076,000 150,917,000 -50,139,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-353,785,000
OpCashFlow TTM
—
Assets (Latest)
$1,112,899,000
Forward EPS
$-1.80

Max Pain — expiry 2027-01-15

max pain strike: $15.00 · spot: $29.12 · call oi: 18,482 · put oi: 1,700

Peers — same industry

TickerNameMarket CapLastDaily %
AVNT AVIENT CORP $3.99B $43.54 —
IPAR INTERPARFUMS INC $4.24B $132.45 —
CSW CSW INDUSTRIALS, INC. $4.39B $269.38 —
SMG SCOTTS MIRACLE-GRO CO $3.64B $62.55 —
CBT CABOT CORP $3.62B $70.14 —

News headlines (Yahoo Finance, 1h cache)

Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
2026-11-16 23:05 · Yahoo
Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?
2026-11-12 08:09 · Yahoo
How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
2026-11-12 01:17 · Yahoo
Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
2026-11-11 21:10 · Yahoo
Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
2026-11-11 10:12 · Yahoo
Definium (DFTX) Q3 2026 Earnings Call Transcript
2026-11-10 02:00 · Yahoo
What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
2026-11-10 01:14 · Yahoo
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-09 21:01 · Yahoo
Definium Therapeutics Announces New Employee Inducement Grants
2026-11-09 12:01 · Yahoo
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
2026-11-04 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.